Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302980 | 1.00 | CHRM3 (0.51) | CHRM3CHRM2 | |
| SCHEMBL1303910 | 0.93 | CHRM3 (0.55) | CHRM3CHRM2 | |
| SCHEMBL1304570 | 0.91 | CHRM3 (0.53) | CHRM3CHRM2 | |
| SCHEMBL1304566 | 0.91 | CHRM3 (0.53) | CHRM3CHRM2 | |
| SCHEMBL1303717 | 0.90 | CHRM2 (0.56) | CHRM3CHRM2 | |
| SCHEMBL1302983 | 0.88 | CHRM2 (0.58) | CHRM3CHRM2 | |
| SCHEMBL1304658 | 0.87 | CHRM3 (0.51) | CHRM3 | |
| SCHEMBL1304661 | 0.87 | CHRM3 (0.51) | CHRM3 | |
| SCHEMBL1302643 | 0.86 | CHRM3 (0.51) | CHRM3 | |
| SCHEMBL1302648 | 0.86 | CHRM3 (0.51) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4837653-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7491736-B2 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-02-17 | — | — | US | claimed |
| JP-2008532922-A | — | — | 2008-08-21 | — | — | JP | claimed |
| EP-1723114-B1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2008-05-14 | — | — | EP | claimed |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | claimed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | claimed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-15 | — | — | US | disclosed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885 |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.